Back to Top Skip to main content Skip to sub-navigation

Blood Lead Level Surveillance Among Pediatric Beneficiaries in the Military Health System, 2010–2017

U.S. Air Force Staff Sgt. Katie Duff, a medical technician with the 193rd Special Operations Wing's Medical Group, pricks the finger of brave 23-month old Kahia Inman, while his mother Malia Duvauchelle holds him during a free health screening. (U.S. Air Force photo by Tech. Sgt. Culeen Shaffer) U.S. Air Force Staff Sgt. Katie Duff, a medical technician with the 193rd Special Operations Wing's Medical Group, pricks the finger of brave 23-month old Kahia Inman, while his mother Malia Duvauchelle holds him during a free health screening. (U.S. Air Force photo by Tech. Sgt. Culeen Shaffer)

Recommended Content:

Medical Surveillance Monthly Report

ABSTRACT

The EpiData Center (EDC) has provided routine blood lead level (BLL) surveillance for Department of Defense (DoD) pediatric beneficiaries since 2011. Data for this study were collected and compiled from raw laboratory test records obtained from the Composite Health Care System Health Level 7 (HL7)-formatted chemistry data, allowing an overview of the number of tests performed and the number of elevated results. Between 2010 and 2017, there were 177,061 tests performed among 162,238 pediatric beneficiaries tested. Using only the highest test result per year for each individual, 169,917 tests were retained for analysis, of which 1,334 (0.79%) test results were considered elevated. The percentage of children with elevated BLLs generally decreased over the time period for children of every service affiliation. All tests throughout this time frame were evaluated using current standards and the protocol followed by the Centers for Disease Control and Prevention and the Department of the Navy (DON). The adoption of a standardized BLL surveillance methodology across the DoD supports a cohesive approach to an evolving public health surveillance topic.

WHAT ARE THE NEW FINDINGS?   

The EDC’s BLL surveillance program established a methodology for lead exposure surveillance among DoD pediatric beneficiaries, providing critical data and valuable historical context for the interpretation of findings. Between 2010 and 2017, the percentage of children with elevated BLLs generally remained below 1.2%, and by 2017, the overall percentage was 0.5% for all children tested.

WHAT IS THE IMPACT ON READINESS AND FORCE HEALTH PROTECTION?

Blood lead surveillance of DON pediatric beneficiaries is required under Bureau of Medicine and Surgery instruction 6200.14D. The EDC’s methodology for BLL surveillance may be leveraged for consistent BLL surveillance across the DoD.

BACKGROUND

Robust lead exposure surveillance is especially important in pediatric populations. There is no safe blood lead level (BLL) for children; even very low BLLs can increase the risk of harmful hematologic and neurologic effects.1 The U.S. Preventive Services Task Force concluded there is currently insufficient evidence to recommend BLL screening of asymptomatic children 5 years of age and younger.2 The Military Health System (MHS) does not require universal BLL screening for pediatric beneficiaries, but providers are directed to consider assessing the risk of lead exposure among children between 6 months and 6 years of age by parental questionnaire, in accordance with recommendations from the American Academy of Pediatrics.3 Children who screen positive on this questionnaire should have their BLLs tested. Additionally, clinical suspicion of lead exposure or poisoning should prompt a blood lead test. Providers should ensure the performance of follow-up care for any child with an elevated BLL, and retesting is recommended to confirm an initial elevated BLL and to monitor the decline in BLLs following treatment.4

Before 2012, a BLL of 10 µg/dL or greater was considered to be an elevated test result.In 2012, the Centers for Disease Control and Prevention (CDC) updated the guidelines for the blood lead reference value (BLRV) to 5 µg/dL or greater, based on National Health and Nutrition Examination Survey results showing declining BLLs in children.6 For an elevated BLL (5 µg/dL or greater) to be considered “confirmed,” CDC requires 1 elevated result from a venous blood test or 2 elevated results from capillary blood tests within 12 weeks.7 Traditional blood lead laboratory test results are the preferred test for Department of the Navy (DON) BLL surveillance. Rapid testing results, like finger-stick tests obtained by MHS providers at the point of care, were used for BLL surveillance purposes until 30 August 2017 when the Bureau of Medicine and Surgery (BUMED) released an instruction stating point-of-care blood testing devices were no longer authorized for compliance with the childhood lead poisoning prevention program in the DON.8

Since 2011, the EpiData Center (EDC) at the Navy and Marine Corps Public Health Center (NMCPHC) has conducted routine BLL surveillance among Department of Defense (DoD) pediatric beneficiaries on a quarterly basis. An annual report based on data at the military treatment facility (MTF) level is also prepared on DON pediatric beneficiaries at the request of the Occupational and Environmental Medicine Department of NMCPHC. All surveillance reports are available to qualified DoD personnel upon request. The EDC’s BLL surveillance program provides critical data and valuable historical context for evaluating lead exposure among DoD pediatric beneficiaries.

This article describes the EDC’s methodology for BLL surveillance in DoD pediatric beneficiaries. This methodology represents a potential model for the development of a shared, standardized BLL surveillance method because it could be tailored to meet the unique needs of each DoD service while also maximizing the comparison, replication, and utility of findings. DON blood lead surveillance is modified from the CDC’s standard blood lead surveillance definitions and classifications to best meet its needs using current capabilities. For every calendar year (CY), the EDC identifies elevated blood lead tests among DON pediatric beneficiaries and then verifies in the Armed Forces Health Longitudinal Technology Application (AHLTA) whether or not the provider followed up with the pediatric beneficiary. The EDC then provides a list of names of children that have not had follow-up testing to the Occupational and Environmental Medicine Department of NMCPHC.

METHODS

Laboratory test records with a sample collection date in CYs 2010–2017 (01 January 2010 through 31 December 2017) were obtained from the Composite Health Care System (CHCS) Health Level 7 (HL7)-formatted chemistry laboratory data. The EDC receives a feed of CHCS HL7-formatted chemistry laboratory data and demographic information daily from the Defense Health Agency. These data include all records from MTFs using the CHCS across the DoD. Records were excluded if the sample was not blood, if the unit of measure or the test result could not be determined, or if the results indicated a test was not performed. For example, before CDC updated its BLRV, 122 test results were recorded as “<10.” These results were removed from the final analysis, as it could not be determined if the results were less than the current BLRV of 5 µg/dL. Blood tests with the same sample collection date and date of certified results were excluded from the final sample, as these tests may have been unauthorized point of care tests8; moreover, it would have been highly unlikely for the laboratories to have been able to collect, analyze, and certify a sample on the same day. Zinc protoporphyrin (ZPP) tests, which measure the amount of ZPP in the blood (an indicator of chronic lead exposure) rather than BLL, were also excluded. If more than 1 BLL test result was identified for an individual in a single year, the highest BLL test result for that year was retained.

BLL tests administered to beneficiary children aged less than 18 years at the date and time of sample collection were included. Tests could either have been those completed within an MHS laboratory or those completed at an out-of-network laboratory, after which an MHS provider received and entered the results into AHLTA. Records were analyzed by sponsor service affiliation (Army, Air Force, Marine Corps, Navy, Other), age group (=6 years and 7–17 years), BLL value (<5 µg/dL, 5–9 µg/dL, 10–19 µg/dL, and =20 µg/dL), and geographic region (outside of the U.S., New England, Mid-Atlantic, Eastern North Central, Western North Central, South Atlantic, Eastern South Central, Western South Central, Mountain, Pacific). For sponsor service affiliation and geographic region, the percentage of elevated BLL tests per year was determined.

RESULTS

From 01 January 2010 through 31 December 2017, 169,917 BLL records were retained for analysis (Table 1). The Army tested more pediatric beneficiaries than any other service affiliation during the reporting period. The majority of testing occurred among pediatric beneficiaries aged 6 years or younger across all branches of service.
Overall, the percentage of elevated BLLs among pediatric beneficiaries decreased from 2010 to 2017 (Figure). Less than 1% of pediatric BLL tests in any service were elevated in 2016 and 2017, and no children in the “other” category had an elevated BLL test since 2014.

For CYs 2010–2017, 96.2% of all BLL tests among pediatric beneficiaries were performed in the U.S. and 3.8% were performed elsewhere (Table 2). The percentages of elevated tests (0.8%) were equivalent for the 2 regions. Within the U.S., there were no tests performed in 9 states. Of all BLL tests in the U.S., 58.8% (n=96,089) were from the South Atlantic and Western South Central regions, which accounted for 54.8% (n=702) of all elevated BLLs. The New England region had the highest regional percentage of elevated BLLs (1.4%), but that percentage was based on just 22 elevated BLLs out of 1,561 tests, the lowest number of tests for any region. Among the states, Texas had the highest number of tests (n=29,340), followed by Virginia (n=25,852), but the percentages of tests with elevated BLLs were just 0.5% and 0.7%, respectively. The 5 states with the highest percentages of elevated BLLs (Connecticut, Rhode Island, Pennsylvania, New Hampshire, and Tennessee) accounted for just 22 elevated levels out of only 268 tests performed (Table 2). Among the remaining 37 states (including Washington, DC) that performed tests, the mean percentage positive was 0.9% and the values ranged from 0.3% (Arizona and Colorado) to 1.8% (Kansas and Mississippi).

EDITORIAL COMMENT

Across the DoD, there were 177,061 tests performed between 2010 and 2017 among 162,238 pediatric beneficiaries. Some children may have had multiple tests occurring within the same year or during the totality of the reporting time frame because they had a positive lead questionnaire screen during a doctor’s visit, exhibited clinical symptoms of lead poisoning per the provider’s discretion, or had a prior elevated BLL test. For surveillance purposes, the highest BLL result per year per pediatric beneficiary was kept for analysis, leading to a final observation count of 169,917 BLL tests.

While the percentage of elevated BLL tests varied by sponsor service affiliation, the overall percentage of elevated BLL tests decreased from 2010 to 2017. The number of BLL tests among pediatric beneficiaries varied by state because of the location of fixed MTFs; however, in general, the percentage of elevated BLL tests did not differ between regions inside and outside of the U.S. The number of children tested within each branch of service likely varied because of the difference in the size of the service populations. Percentages of children with elevated BLLs could potentially be affected by the number of children tested within a branch of service or geographic region, whether the children tested were at a lower or higher risk of lead exposure, and the screening recommendations of the MHS.

To adequately identify and address lead exposure risks in their active duty and beneficiary populations, the DON and other DoD services might consider the adoption of a single, standardized method for BLL surveillance. A shared methodology would facilitate comparisons and reduce duplicative effort across the services. Ideally, a shared methodology would also be flexible and responsive to accommodate the challenges related to BLL surveillance in the DoD.

HL7-formatted data are routinely generated within the CHCS at fixed MTFs. HL7-formatted data do not include records from BLL tests without certified results. This may include specimens collected at an MTF that were sent to an out-of-network laboratory for testing. Data from Purchased CareThe TRICARE Health Program is often referred to as purchased care. It is the services we “purchase” through the managed care support contracts.purchased care providers also were not included. Records from MHS GENESIS, a new electronic health record that launched in February 2017 at select MHS facilities, were unavailable. Therefore, records from the following MTFs throughout the Pacific Northwest region were not included in this analysis after the launch of MHS GENESIS at their facilities: Fairchild Air Force Base, Madigan Army Medical Center, Naval Health Clinic Oak Harbor, and Naval Hospital Bremerton. Changes in civilian and military testing policies, updates to exposure thresholds, population- or service-specific practices, and data limitations complicate comparisons over time and across services and limit the generalizability of findings.

The HL7-formatted chemistry database consists of nonculture laboratory test results (e.g., polymerase chain reaction and antigen testing). Providers may order a panel when patients present with nonspecific symptoms. If the test name or test results within a panel are not disease-specific, these results may not be captured in search terms used to query the chemistry data. Classifying chemistry tests involves extensive searching of free-text test result fields. It is possible that some test results were misclassified, though validation steps were included to reduce error. Venous and capillary BLL specimen samples are unable to be distinguished in the HL7-formatted chemistry data. Capillary specimen samples for lead testing are generally viewed as less reliable than venous samples because of the potential for lead contamination of specimens during collection that could result in false positives. For surveillance purposes, the EDC reports the highest BLL result per year per pediatric beneficiary and ensures that there is follow-up regarding that elevated test regardless of specimen sample type.

Universal BLL screening is not required in the MHS but is based on the discretion of healthcare practitioners. As a result, the proportion of pediatric beneficiaries with high BLLs may not be a true representation of the BLLs in the pediatric beneficiary population. However, the EDC’s pediatric BLL surveillance methods may provide a starting point for discussions on the value of developing a standardized blood lead surveillance program across all DoD services.

Author affiliations: EpiData Center, Navy and Marine Corps Public Health Center, Portsmouth, VA (Ms. Kotas, Ms. Madden, Ms. Luse, and Ms. Carroll).

Acknowledgments: The authors thank Ashleigh McCabe and Angela Schlein for their support of this analysis and manuscript.

Disclaimers: The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. The authors are employees of the U.S. Government. This work was prepared as part of their official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C., §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties. This research was supported in part by an appointment to the Postgraduate Research Participation Program at the Navy and Marine Corps Public Health Center administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the Navy and Marine Corps Public Health Center.

REFERENCES

1. Centers for Disease Control and Prevention. Health effects of lead exposure. https://www.cdc.gov/nceh/lead/prevention/health-effects.htm. Accessed 05 March 2020.

2. U.S. Preventive Services Task Force. Elevated blood lead levels in children and pregnant women: screening. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/elevated-blood-lead-levels-in-childhood-and-pregnancy-screening. Accessed 05 March 2020.

3. American Academy of Pediatrics. Detection of lead poisoning. https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/lead-exposure/Pages/Detection-of-Lead-Poisoning.aspx. Accessed 05 March 2020.

4. Advisory Committee on Childhood Lead Poisoning Prevention, Centers for Disease Control and Prevention. Low level lead exposure harms children: a renewed call for primary prevention. https://www.cdc.gov/nceh/lead/ACCLPP/Final_Document_030712.pdf. Accessed 05 March 2020.

5. Centers for Disease Control and Prevention. Preventing lead poisoning in young children. https://wonder.cdc.gov/wonder/prevguid/p0000029/p0000029.asp. Accessed 05 March 2020.

6. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES). https://www.cdc.gov/nceh/lead/data/nhanes.htm. Accessed 05 March 2020.

7. Centers for Disease Control and Prevention. Standard surveillance definitions and classifications. https://www.cdc.gov/nceh/lead/data/casedefinitions-classifications.htm. Accessed 05 March 2020.

8. Department of the Navy, Bureau of Medicine and Surgery. BUMED Instruction 6200.14D. Childhood Lead Poisoning Prevention. 30 August 2017.

Percentage of elevated (=5 µg/dL) pediatric BLL tests, by sponsor service affiliation, 2010–2017

Pediatric BLLs, by sponsor service affiliation and age group, 2010–2017

Number and percentage of elevated (=5 µg/dL) pediatric BLLs, by region and state, 2010–2017

You also may be interested in...

Vasectomy and Vasectomy Reversals, Active Component, U.S. Armed Forces, 2000–2017

Article
3/1/2019
Sperm is the male reproductive cell  Photo: iStock

During 2000–2017, a total of 170,878 active component service members underwent a first-occurring vasectomy, for a crude overall incidence rate of 8.6 cases per 1,000 person-years (p-yrs). Among the men who underwent incident vasectomy, 2.2% had another vasectomy performed during the surveillance period. Compared to their respective counterparts, the overall rates of vasectomy were highest among service men aged 30–39 years, non-Hispanic whites, married men, and those in pilot/air crew occupations. Male Air Force members had the highest overall incidence of vasectomy and men in the Marine Corps, the lowest. Crude annual vasectomy rates among service men increased slightly between 2000 and 2017. The largest increases in rates over the 18-year period occurred among service men aged 35–49 years and among men working as pilots/air crew. Among those who underwent vasectomy, 1.8% also had at least 1 vasectomy reversal during the surveillance period. The likelihood of vasectomy reversal decreased with advancing age. Non-Hispanic black and Hispanic service men were more likely than those of other race/ethnicity groups to undergo vasectomy reversals.

Recommended Content:

Medical Surveillance Monthly Report

Testosterone Replacement Therapy Use Among Active Component Service Men, 2017

Article
3/1/2019
Anopheles merus

This analysis summarizes the prevalence of testosterone replacement therapy (TRT) during 2017 among active component service men by demographic and military characteristics. This analysis also determines the percentage of those receiving TRT in 2017 who had an indication for receiving TRT using the 2018 American Urological Association (AUA) clinical practice guidelines. In 2017, 5,093 of 1,076,633 active component service men filled a prescription for TRT, for a period prevalence of 4.7 per 1,000 male service members. After adjustment for covariates, the prevalence of TRT use remained highest among Army members, senior enlisted members, warrant officers, non-Hispanic whites, American Indians/Alaska Natives, those in combat arms occupations, healthcare workers, those who were married, and those with other/unknown marital status. Among active component male service members who received TRT in 2017, only 44.5% met the 2018 AUA clinical practice guidelines for receiving TRT.

Recommended Content:

Medical Surveillance Monthly Report

Outbreak of Acute Respiratory Illness Associated with Adenovirus Type 4 at the U.S. Naval Academy, 2016

Article
2/1/2019
Malaria case definition

Human adenoviruses (HAdVs) are known to cause respiratory illness outbreaks at basic military training (BMT) sites. HAdV type-4 and -7 vaccines are routinely administered at enlisted BMT sites, but not at military academies. During August–September 2016, U.S. Naval Academy clinical staff noted an increase in students presenting with acute respiratory illness (ARI). An investigation was conducted to determine the extent and cause of the outbreak. During 22 August–11 September 2016, 652 clinic visits for ARI were identified using electronic health records. HAdV-4 was confirmed by real-time polymerase chain reaction assay in 18 out of 33 patient specimens collected and 1 additional HAdV case was detected from hospital records. Two HAdV-4 positive patients were treated for pneumonia including 1 hospitalized patient. Molecular analysis of 4 HAdV-4 isolates identified genome type 4a1, which is considered vaccine-preventable. Understanding the impact of HAdV in congregate settings other than enlisted BMT sites is necessary to inform discussions regarding future HAdV vaccine strategy.

Recommended Content:

Medical Surveillance Monthly Report

Update: Malaria, U.S. Armed Forces, 2018

Article
2/1/2019
Anopheles merus

Malaria infection remains an important health threat to U.S. service mem­bers who are located in endemic areas because of long-term duty assign­ments, participation in shorter-term contingency operations, or personal travel. In 2018, a total of 58 service members were diagnosed with or reported to have malaria. This represents a 65.7% increase from the 35 cases identi­fied in 2017. The relatively low numbers of cases during 2012–2018 mainly reflect decreases in cases acquired in Afghanistan, a reduction due largely to the progressive withdrawal of U.S. forces from that country. The percentage of cases of malaria caused by unspecified agents (63.8%; n=37) in 2018 was the highest during any given year of the surveillance period. The percent­age of cases identified as having been caused by Plasmodium vivax (10.3%; n=6) in 2018 was the lowest observed during the 10-year surveillance period. The percentage of malaria cases attributed to P. falciparum (25.9 %) in 2018 was similar to that observed in 2017 (25.7%), although the number of cases increased. Malaria was diagnosed at or reported from 31 different medical facilities in the U.S., Afghanistan, Italy, Germany, Djibouti, and Korea. Pro­viders of medical care to military members should be knowledgeable of and vigilant for clinical manifestations of malaria outside of endemic areas.

Recommended Content:

Medical Surveillance Monthly Report

Update: Incidence of Glaucoma Diagnoses, Active Component, U.S. Armed Forces, 2013–2017

Article
2/1/2019
Glaucoma

Glaucoma is an eye disease that involves progressive optic nerve damage and vision loss, leading to blindness if undetected or untreated. This report describes an analysis using the Defense Medical Surveillance System to identify all active component service members with an incident diagnosis of glaucoma during the period between 2013 and 2017. The analysis identified 37,718 incident cases of glaucoma and an overall incidence rate of 5.9 cases per 1,000 person-years (p-yrs). The majority of cases (97.6%) were diagnosed at an early stage as borderline glaucoma; of these borderline cases, 2.2% progressed to open-angle glaucoma during the study period. No incident cases of absolute glaucoma, or total blindness, were identified. Rates of glaucoma were higher among non-Hispanic black (11.0 per 1,000 p-yrs), Asian/Pacific Islander (9.5), and Hispanic (6.9) service members, compared with non-Hispanic white (4.0) service members. Rates among female service members (6.6 per 1,000 p-yrs) were higher than those among male service members (5.8). Between 2013 and 2017, incidence rates of glaucoma diagnoses increased by 75.4% among all service members.

Recommended Content:

Medical Surveillance Monthly Report

Re-evaluation of the MSMR Case Definition for Incident Cases of Malaria

Article
2/1/2019
Anopheles merus

The MSMR has been publishing the results of surveillance studies of malaria since 1995. The standard MSMR case definition uses Medical Event Reports and records of hospitalizations in counting cases of malaria. This report summarizes the performance of the standard MSMR case definition in estimating incident cases of malaria from 2015 through 2017. Also explored was the potential surveillance value of including outpatient encounters with diagnoses of malaria or positive laboratory tests for malaria in the case definition. The study corroborated the relative accuracy of the MSMR case definition in estimating malaria incidence and provided the basis for updating the case definition in 2019 to include positive laboratory tests for malaria antigen within 30 days of an outpatient diagnosis.

Recommended Content:

Medical Surveillance Monthly Report

Non-alcoholic fatty liver disease

Infographic
1/29/2019
HPV

At the time of this report, there were no published studies of non-alcoholic fatty liver disease (NAFLD) incidence over time among active component U.S. military personnel. Examining the incidence rates of NAFLD and their temporal trends among active component U.S. military members can provide insights into the future burden of NAFLD on the MHS.

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health

Cardiovascular disease-related medical evacuations

Infographic
1/29/2019
Cardiovascular disease-related medical evacuations

This descriptive analysis summarizes the demographic characteristics, counts, rates and temporal trends for Cardiovascular disease-related medical evacuations from the CENTCOM area of responsibility. In addition, the percentage of those evacuated who had received pre-deployment diagnoses indicating cardiovascular risk is summarized. Responses to questions regarding health status and physician referrals on the DD2795 are also summarized.

Recommended Content:

Health Readiness | Armed Forces Health Surveillance Branch | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health

Acute Flaccid Myelitis Case Reporting

Infographic
1/29/2019
Acute Flaccid Myelitis Case Reporting

This case highlights important clinical characteristics of acute flaccid myelitis and emphasizes the importance of including AFM in the differential diagnosis when evaluating active duty service members and Military Health System beneficiaries presenting with paralysis.

Recommended Content:

Health Readiness | Epidemiology and Analysis | Medical Surveillance Monthly Report | Public Health

Cardiovascular Disease-related Medical Evacuations, Active and Reserve Components, U.S. Armed Forces, 1 October 2001–31 December 2017

Article
1/1/2019

From 1 October 2001 through 31 December 2017, a total of 697 medical evacuations of service members from the U.S. Central Command (CENTCOM) area of responsibility were followed by at least one medical encounter in a fixed medical facility outside the operational theater with a diagnosis of a cardiovascular disease (CVD). The vast majority of those (n=660; 94.7%) evacuated were males. More than a third of CVD-related evacuations (n=278, 39.9%) occurred in service members 45 years of age or older; slightly more than half (n=369; 52.9%) occurred in reserve or guard members. The most common CVD risk factors which had been diagnosed among evacuated service members prior to their deployment were hypertension (n=236; 33.9%) and hyperlipidemia (n=241; 34.9%). Much lower percentages had been previously diagnosed with obesity (n=74, 10.6%) or diabetes (n=21, 3.0%). More than 1 in 4 service members with a CVD-related medical evacuation had been diagnosed with more than one risk factor (n=182, 26.1%). Both limitations to the data available and strategies to reduce CVD morbidity in theater are discussed.31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Acute Flaccid Myelitis: Case Report

Article
1/1/2019

In August 2018, the U.S. Centers for Disease Control and Prevention (CDC) noted an increased number of reports of patients in the U.S. having symptoms clinically compatible with acute flaccid myelitis (AFM). AFM is characterized by rapid onset of flaccid weakness in one or more limbs and distinct abnormalities of the spinal cord gray matter on magnetic resonance imaging (MRI). Clinical and laboratory data suggest that AFM is associated with an antecedent viral infection. AFM may be difficult to differentiate from other causes of paralysis and, given that it is rare, has the potential to be overlooked. This case highlights important clinical characteristics of AFM and emphasizes the importance of including AFM in the differential diagnosis when evaluating active duty service members and Military Health System (MHS) beneficiaries presenting with paralysis.31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Historical Perspective: Leptospirosis Outbreaks Affecting Military Forces

Article
1/1/2019

Leptospirosis is a widespread and highly prevalent bacterial zoonotic disease that is caused by pathogenic spirochetes of the genus Leptospira. It is transmitted to humans primarily through contact of abraded skin or mucous membranes with water or wet soil that has been contaminated with infected animal urine. Many wild and domestic animals are susceptible to infection by pathogenic Leptospira bacteria including rats, dogs, cattle, goats, sheep, and swine. Once chronically infected, a carrier animal can shed Leptospira bacteria in urine for long periods of time and Leptospira bacteria can survive in water or soil for weeks to months.higher among non-Hispanic white service members compared with those in other race/ethnicity groups. In both sexes, the annual rates of adrenal insufficiency and other disorders of adrenal gland increased slightly during the 16-year period.31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Non-alcoholic Fatty Liver Disease (NAFLD), Active Component, U.S. Armed Forces, 2000–2017

Article
1/1/2019

During 2002–2017, the most common incident adrenal gland disorder among male and female service members was adrenal insufficiency and the least common was adrenomedullary hyperfunction. Adrenal insufficiency was diagnosed among 267 females (crude overall incidence rate: 8.2 cases per 100,000 person-years [p-yrs]) and 729 males (3.9 per 100,000 p-yrs). In both sexes, overall rates of other disorders of adrenal gland and Cushing’s syndrome were lower than for adrenal insufficiency but higher than for hyperaldosteronism, adrenogenital disorders, and adrenomedullary hyperfunction. Crude overall rates of adrenal gland disorders among females tended to be higher than those of males, with female:male rate ratios ranging from 2.1 for adrenal insufficiency to 5.5 for androgenital disorders and Cushing’s syndrome. The highest overall rates of adrenal insufficiency for males and females were among non-Hispanic white service members. Among females, rates of Cushing’s syndrome and other disorders of adrenal gland were 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Adrenal Gland Disorders, Active Component, U.S. Armed Forces, 2002–2017

Article
12/1/2018

During 2002–2017, the most common incident adrenal gland disorder among male and female service members was adrenal insufficiency and the least common was adrenomedullary hyperfunction. Adrenal insufficiency was diagnosed among 267 females (crude overall incidence rate: 8.2 cases per 100,000 person-years [p-yrs]) and 729 males (3.9 per 100,000 p-yrs). In both sexes, overall rates of other disorders of adrenal gland and Cushing’s syndrome were lower than for adrenal insufficiency but higher than for hyperaldosteronism, adrenogenital disorders, and adrenomedullary hyperfunction. Crude overall rates of adrenal gland disorders among females tended to be higher than those of males, with female:male rate ratios ranging from 2.1 for adrenal insufficiency to 5.5 for androgenital disorders and Cushing’s syndrome. The highest overall rates of adrenal insufficiency for males and females were among non-Hispanic white service members. Among females, rates of Cushing’s syndrome and other disorders of adrenal gland were 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Incidence and Prevalence of the Metabolic Syndrome Using ICD-9 and ICD-10 Diagnostic Codes, Active Component, U.S. Armed Forces, 2002–2017

Article
12/1/2018

This report uses ICD-9 and ICD-10 codes (277.7 and E88.81, respectively) for the metabolic syndrome (MetS) to summarize trends in the incidence and prevalence of this condition among active component members of the U.S. Armed Forces between 2002 and 2017. During this period, the crude overall incidence rate of MetS was 7.5 cases per 100,000 person-years (p-yrs). Compared to their respective counterparts, overall incidence rates were highest among Asian/Pacific Islanders, Air Force members, and warrant officers and were lowest among those of other/unknown race/ethnicity, Marine Corps members, and junior enlisted personnel and officers. During 2002–2017, the annual incidence rates of MetS peaked in 2009 at 11.6 cases per 100,000 p-yrs and decreased to 5.9 cases per 100,000 p-yrs in 2017. Annual prevalence rates of MetS increased steadily during the first 11 years of the surveillance period reaching a high of 38.9 per 100,000 active component service members in 2012, after which rates declined slightly to 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report
<< < ... 6 7 8 9 10  ... > >> 
Showing results 136 - 150 Page 10 of 13

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.